Serotoninergic Pathways in Sudden and Unexpted Death in Epilepsy (SUDEP)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

2 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-01-31

Study Completion Date

2019-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The mortality rate is increased in patients with epilepsy, and especially among patients with drug-resistant epilepsy. This increased mortality is mainly related to the risk of SUDEP whose incidence is between 3.5 and 9 per 1,000 for patients with drug-resistant epilepsy. The term SUDEP refers to a sudden death occurring in a patient with epilepsy in whom anamnestic and post-mortem evidence does not identify a particular cause. Experimental and clinical data strongly suggest that most of SUDEP result from a postictal respiratory dysfunction progressing to terminal apnea. Due to the major role of serotonin in regulating breathing rhythms and data in animal models of epilepsy, it is envisaged that an alteration of serotonergic systems of the brainstem and limbic regions may play a central role in the occurrence of SUDEP. The objective of this work is to look for abnormalities of the serotonergic transmission within regulatory regions of respiratory and autonomic functions in brain samples prospectively collected in patients died from SUDEP.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

National Network for the Study of Predictors and Prevention of Sudden Unexpected Death in Drug-resistant Partial Epilepsies

NCT02572297

Drug-resistant Partial Epilepsy

COMPLETED

Risk Factors for Sudden Unexplained Death in Epilepsy

NCT01662453

SUDEP

RECRUITING

Circulating microRNAs as Biomarkers of RESPIratory Dysfunction in Patients With Refractory epilePSY

NCT03419000

Drug Resistant Epilepsy

COMPLETED NA

Efficacy of Naloxone in Reducing Postictal Central Respiratory Dysfunction in Patients With Epilepsy

NCT02332447

Epilepsy

COMPLETED PHASE3

Efficacy of Fluoxetine Against Seizure-induced Central Apneas

NCT02569970

Epilepsy Ictal/Post-ictal Hypoxemia

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sudden Unexpected Death in Epilepsy (SUDEP)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

diagnostic of SUDEP

patient with epilepsy in whom anamnestic and post-mortem evidence does not identify a particular cause (diagnosis of SUDEP). Brain samples and skin samples are collected.

Brain samples

Intervention Type OTHER

Collected in patients died

Skin samples

Intervention Type OTHER

Collected in patients died

Control 1

Subjects with a known epilepsy, whose death is linked to a specific cause. Brain samples and skin samples are collected.

Brain samples

Intervention Type OTHER

Collected in patients died

Skin samples

Intervention Type OTHER

Collected in patients died

Control 2

Subjects without known pathological history, remained victims of unexplained sudden unexpected death (SUDEP) after all investigations and for which a heart rhythm disorder is suspected in first intention. Brain samples and skin samples are collected.

Brain samples

Intervention Type OTHER

Collected in patients died

Skin samples

Intervention Type OTHER

Collected in patients died

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Brain samples

Collected in patients died

Intervention Type OTHER

Skin samples

Collected in patients died

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>18 years
* Postmortem time before autopsy \<30 hours

Exclusion Criteria

* Age \<18 years
* postmortem time before autopsy \> 30 hours
* Any subject whose brain would be of forensic interest
* Any patient who expressed an opposition to organ donation.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No